Anti-Rheumatic Rx

EULAR 2023 – Day 4 Report

Save

Jack Cush, MD

Jun 05, 2023

Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining. Many people missed the last day (June 3rd) of the meeting as a pending Milan airport strike on

Read Article

Clinically suspect arthralgias: justified or artefact?

Save

David Liew

Jun 05, 2023

Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias. At EULAR 2023 in Milan, the perfect platform was provided for an airing of grievances, in a

Read Article

Important from @cappelliMD @jhrheumatology irAE cohort on predictors of DMARD requirement in ICI-inflammatory arthritis, and persistent ICI-IA post-ICI cessation. The better we can predict these patients, the more we can get the right therapy early POS0951 #EULAR2023 @RheumNow https://t.co/YGTRl71505

David Liew @drdavidliew( View Tweet )

Jun 03, 2023

The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 03, 2023

meds for PsA at #EULAR2023 recommendations bDMARD after csDMARD (no order proposed) @RheumNow https://t.co/bHMG4A8nmP

Bella Mehta @bella_mehta( View Tweet )

Jun 03, 2023

How do we improve MTX adherence? Biochemical measure of MTX adherence 37% of patients starting a biologic do not take their MTX (!) Those who do respond better to first Biologic at 6 Mo than those who don’t 37% biologic responders = non adherent POS0313 #EULAR23 @Rheumnow https://t.co/L1Mkqpg1Aj

Aurelie Najm @AurelieRheumo( View Tweet )

Jun 03, 2023

EULAR 2023 – Day 3 Report

Save

Jack Cush, MD

Jun 02, 2023

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.

Read Article

The key data for treating clinically suspect arthralgias (CSA): TREAT-EARLIER (MTX) ARIAA, APIPPRA (abatacept) but what we need to do going forward: stratify pts better for studies predict individual risk better, to weight up risk-benefit of intervention #EULAR2023 @RheumNow https://t.co/h3gNIyLxPY

David Liew @drdavidliew( View Tweet )

Jun 02, 2023

Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8

Dr. John Cush @RheumNow( View Tweet )

Jun 02, 2023

Study on folylPG synthétase (FPGS) activity and MTX-PG measured in sperm showed low bio active form of MTX-PG, low FPGS activity resulting in lower capacity to form MTX-PG, Perez-Garcia LF, Abst#OP0224 #EULAR2023 @RheumNow https://t.co/8sGQOBxn8r

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 02, 2023

Herpes Zoster vaccination in RA patients treated with Upadacitinib and MTX showed a satisfactory response, slight reduction in response compared to general population in both antibody and cell mediated responses Winthrop K, Abst#OP0225 #EULAR2023 @RheumNow https://t.co/wxwbOYsn5K

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 02, 2023

To treat or not? Clinically suspect arthralgia does affect QoL including function. Both premises of treating with a DMARD are valid. OverRx v missing the very early window of opportunity @RheumNow #EULAR2023 @eular_org https://t.co/86CVZ2IjEf

Janet Pope @Janetbirdope( View Tweet )

Jun 02, 2023

For our rheum patients who have had cancer previously - the default can’t be to not have DMARDs. @eular_org points to consider SLR: no clear risk, across b/tsDMARDs For too long these patients were unnecessarily asked to ride it out. No more please POS1069 #EULAR2023 @RheumNow https://t.co/7m4Yh0h7rd

David Liew @drdavidliew( View Tweet )

Jun 02, 2023

Should immunosuppression be used to improve #PAH in #SSc added to PAH Rx (85%) Morbidity or mortality outcomes >700 pts - half had a DMARD after dx RheumNow #EULAR2023 OP0238 Targeted Rx improved esp RTX\TCZ findings V interesting results #GameChanger May change my Rx practice!

Janet Pope @Janetbirdope( View Tweet )

Jun 02, 2023

Retro French database study shows reassuring data. Overall mortality after IRAEs =similar between pts receiving b/tsDMARDs vs. those who don't 70000+ pts treated w/ ICI, 7800+ IRAEs (most frequent colitis) & 330 treated w/ b/tsDMARDs, 10% Rheum IRAE OP0270 @RheumNow #EULAR23 https://t.co/OFNaIU4kzt

Aurelie Najm @AurelieRheumo( View Tweet )

Jun 02, 2023

Malignancy in real world datasets: do we see differences between DMARDs - particularly JAKi, with ORAL Surveillance in mind? RABBIT German data (limited risk window): Point estimates slightly up vs TNFi, esp in high CV risk pts but magnitude not big OP0218 #EULAR2023 @RheumNow https://t.co/Ou7TgWvf3b

David Liew @drdavidliew( View Tweet )

Jun 02, 2023

Men trying to conceive were prev told to avoid MTX. Another myth busted Why? Spermatozoa lack the FPGS enzyme responsible for MTX-PG metabolism, the tiny amount of MTX-PG in sperm isn’t active. No quality issues! OP0224 #EULAR2023 @RheumNow (& @ARD_BMJ https://t.co/SDdoNP12oR)

Links:

Is methotrexate safe for men with an immune-mediated inflammatory disease and a…

David Liew @drdavidliew( View Tweet )

Jun 02, 2023

EULAR 2023 – Day 2 Report

Save

Jack Cush, MD

Jun 01, 2023

Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial

Read Article

Obesity in #AOSD – predicted the development of a chronic disease course and biologic DMARD failure, 139 pts with AOSD- 19% Obese (BMI>30) observational study. abst#AB1503 #EULAR2023 @rheumnow

Bella Mehta @bella_mehta( View Tweet )

Jun 01, 2023

ANSWER cohort Retrospective study 6600+ bio/tsDMARDs ttmt courses, 20 yrs ✔️IL-6Ri is the lowest discontinued for lack of efficacy ✔️CTLA4-Ig is the lowest discontinued due to AEs ✔️Concomitant GC ⬆️30% drug discontinuation due to AEs @Rheumnow #EULAR23 POS0051 https://t.co/8e6U5KHmX4

Aurelie Najm @AurelieRheumo( View Tweet )

Jun 01, 2023

Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0

Dr. John Cush @RheumNow( View Tweet )

Jun 01, 2023

CareRA trial: 3 months addition of LEF vs. ETA in pts resistant to COBRA-Slim regimen (MTX 15 mg/w + step-down prednisone): After 2 years, no difference in dis control but those who received ETA early were treated more frequently w/ csDMARD monotherapy #EULAR23 @RheumNow OP0129 https://t.co/YwSoZWi375

Aurelie Najm @AurelieRheumo( View Tweet )

Jun 01, 2023

“You don’t need MTX with TCZ for RA” Err, well: - just like TNFi, you def can get ADAb to TCZ - they definitely lead to lower response rates - MTX co-admin reduces ADAb Seems like a good idea to me, but your call 🤷‍♂️ Bitoun, Mariette et al POS0630 #EULAR2023 @RheumNow https://t.co/2jOAqA6YZ3

David Liew @drdavidliew( View Tweet )

Jun 01, 2023

No relationship between MTX-PG levels in terms of efficacy by SDAI remission but higher MTX-PG levels related to adverse events by Tamai H, Abstr #OP0128 #EULAR2023 @RheumNow https://t.co/TiO5eeYlnS

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 01, 2023

How much MTX do we need with adalimumab in RA? Can blood concentrations help? MTX RBC polygluts: - don’t seem to match to efficacy - do seem match to safety, a bit (no ADAb data here) *One day* we’ll get better at what MTX dose is needed with TNFi #EULAR2023 OP0128 @RheumNow https://t.co/OGM3hxr4fG

David Liew @drdavidliew( View Tweet )

Jun 01, 2023